Background We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for
chemotherapy-naïve patients with metastatic pancreatic cancer. Methods Patients with …

FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic
pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX …

The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for
Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine …

Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …

The introduction of the FOLFIRINOX regimen within the last decade marked the first
progress in the clinical field of metastatic pancreatic cancer which had not seen any …

Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …

Abstract Background Although FOLFIRINOX (5-Fluorouracil+ leucovorin+ irinotecan+
oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer …

Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …

Background FOLFIRINOX (FX) has been reported as an effective treatment for unresectable
advanced pancreatic cancer. However, FX is associated with a high incidence of adverse …

Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-
line treatments in patients with metastatic pancreatic cancer (mPC). However, data …